HK Stock Market Move | LEPU BIO (02157) continues to rise by over 7%, MRG007 is expected to become a potential best-in-class (BIC) drug.

LEPU BIO (02157) rose by over 7%, with a cumulative increase of nearly 30% since the beginning of the month. As of the time of writing, it has risen by 6.01% to 4.94 Hong Kong dollars, with a trading volume of 32.6214 million Hong Kong dollars. On the news front, LEPU BIO's MRG007 clinical application was officially accepted by the National Medical Products Administration's Drug Evaluation Center (CDE) in May of this year. This marks a crucial milestone in its clinical development in the field of gastrointestinal tumors, and it is expected to bring a new treatment option for millions of advanced gastrointestinal tumor patients in China. Northeast noted that MRG007, as the flagship pipeline that set a record of 1.2 billion USD in overseas licensing for LEPU BIO, the acceptance of the CDE clinical application is an important milestone in its global development process. With its differentiated technological advantages, MRG007 has the potential to become the best-in-class (BIC) drug in its category, further solidifying the company's leading position in the field of gastrointestinal tumor ADCs, and laying a strong foundation for future global multicenter clinical development and potential more BD collaborations.